drugset / Trial / NCT01602887

Relative Bioavailability Study

NCT01602887

Phase 1 Completed 24 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This is a BA study comparing the bioavailability of two new capsule formulations and one solution formulation to the isethionate capsule used in phase 1 and 2 trials in healthy volunteers.

Timeline

Start
2012-05
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 50 mg Oral
Subject Palbociclib Small molecule 125 mg Oral

Indications

No indication recorded.